A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Trial Profile

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms ZUMA-3
  • Sponsors Kite Pharma
  • Most Recent Events

    • 12 Sep 2017 Preliminary results (n=11; data cut off 12/31/2016) presented at the 42nd European Society for Medical Oncology Congress
    • 08 Aug 2017 According to a Kite Pharma media release, the company expects preliminary follow-up phase 1 data from ZUMA-3 and ZUMA-4 studies and advance these studies into phase 2 in the second half of 2017.
    • 25 Jun 2017 Results from phase I portion of the trial (n=11; As of Nov 1, 2016) presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top